Probleme bei der Behandlung mit Kalziumantagonisten

Überblick für die Praxis
  • G. Bönner
Part of the Aktuelle Therapieprinzipien in Kardiologie und Angiologie book series (THERAPIEPRINZ.)

Zusammenfassung

Von den subjektiven Nebenwirkungen imponieren für die Kalziumantagonisten, besonders die des Nifedipintyps, am stärksten Flush, Kopfschmerzen und Schwindel.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abadie E, Passa P (1984) Diabetogenic effects of nifedipine. Br Med J 289: 438CrossRefGoogle Scholar
  2. Anderton JL, Vallance BD, Stanley NN, Crowe PF, Mittra B, Perks WH (1988) Atenolol and sustained release nifedipine alone and in combination in hypertension - a randomized, double- blind, cross-over study. Drug 35 [Suppl 4]: 22–26CrossRefGoogle Scholar
  3. Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, Tabatznik B, Liang C, Heupier F, Achuff S, Reichek N, Geltman E, Kerin NZ, Neff RK, Braunwald E (1980) Nifedipine therapy for coronary-artery spasm. N Engl J Med 302: 1269–1273PubMedCrossRefGoogle Scholar
  4. Arrigo F, Consolo F (1987) Long-term treatment of essential hypertension with slow-release nifedipine. Curr Therapeut Res 41: 651–664Google Scholar
  5. Arzneitelegramm (1986) Gynäkomastie und Nifedipin. Arzneitelegramm 4: 32Google Scholar
  6. Barak S, Engelberg IS, Hiss J (1987) Gingival hyperplasia caused by nifedipine. J Periodontol 58: 639–642PubMedGoogle Scholar
  7. Bauer LA, Stenwall M, Horn JR, Davis R, Opheim K, Greene L (1986) Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Clin Pharmacol Ther 40: 239–242PubMedCrossRefGoogle Scholar
  8. Belz GG, Doering W, Munkes R, Matthews J (1983) Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther 33: 410–417PubMedCrossRefGoogle Scholar
  9. Berman JL (1985) Dysomia, Dysgeusia and Diltiazem. Ann Intern Med 102: 717PubMedGoogle Scholar
  10. Bhatnagar SK, Amin MMA, Al-Yusuf AR (1984) Diabetogenic effects of nifedipine. Br Med J 289: 19CrossRefGoogle Scholar
  11. Biamino G, Oeff M, Prokein E, Schröder R (1982) Verhalten von Hämodynamik und Koronardurchblutung nach intravenöser Gabe von Diltiazem bei koronarer Herzerkrankung. In: Bender F, Greeff K (eds) Calciumantagonisten zur Behandlung der Angina pectoris, Hypertonie und Arrhythmie. Excerpta Medica, Amsterdam, pp 94–105Google Scholar
  12. Bonetti A, del Prato C, Orlandini G, Zuliani U (1979) Influenza della somministrazione acuta di un calcio-antagonista (nifedipina) sul metabolismo glico-lipidico. Gazeta Arteriosclerol 4: 287–289Google Scholar
  13. Bosch X, Campistol JM, Botey A, Cases A, Revert LL (1986) Nifedipine-induced parotitis. Lancet 11: 467CrossRefGoogle Scholar
  14. Bosso JV, Gazzara PC, Rosati M (1986) Tetany associated with nifedipine. N Engl J Med 315: 584–585PubMedCrossRefGoogle Scholar
  15. Bourbigot B, Guiserix J, Airiau J, Bressollette L, Morin JF, Cledes J (1986) Nicardipine increases cyclosporin blood levels. Lancet 1: 1447PubMedCrossRefGoogle Scholar
  16. Braunwald E (1984) Heart disease - A textbook of cardiovascular medicine. Saunders, PhiladelphiaGoogle Scholar
  17. Brodmerkel GJ (1983) Nifedipine and erythromelalgia. Ann Intern Med 99: 415PubMedGoogle Scholar
  18. Brodsky SJ, Cutler SS, Weiner DA, Klein MD (1981) hepatotoxicity due to treatment with verapamil. Ann Intern Med 94: 490–491Google Scholar
  19. Bussmann WD, Hopf R (1985) Kalziumantagonisten in der Therapie der koronaren Herzerkrankung. Inn Med 12: 255–258Google Scholar
  20. Butler RT, Kalkwarf KL, Kaidahl WB (1987) Drug-induced gingival hyperplasia: phenytoin, cyclosporine, and nifedipine. J Am Dent Assoc 114: 56–60PubMedGoogle Scholar
  21. Cagatay M, Frost N, Weiss KH, Wiesner K (1987) Assessment of longterm efficacy and tolerabi- lity of nisoldipine by the clinical data pool. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 201–209Google Scholar
  22. Cassagnes J, Lamaison D, Palcoux MC, Lusson JR, Fanget M, Gachy B, Teyssoneyre B, Jallut H (1980) Traitement dy syndrome de menace par le diltiazem. Therapie 35: 465–473PubMedGoogle Scholar
  23. Chaffman M, Brodgen RN (1985) Diltiazem - a review of its pharmacological properties and therapeutic efficacy. Drugs 29: 387–454PubMedCrossRefGoogle Scholar
  24. Chan LFT, Chhuy LH, Crowley RJ (1987) Verapamil tissue concentrations in fatal cases. J Analyt Toxicol 11: 171–174Google Scholar
  25. Charles S, Ketelslegers JM, Buysschaert M, Lambert AE (1981) Hyperglycaemic effect of nifedipine. Br Med J 283: 19–20CrossRefGoogle Scholar
  26. Cheymol G, Weissenburger J (1981) Les effets indsirables des medicaments inhibant les mouvements du calcium. Therapie 36: 135–142PubMedGoogle Scholar
  27. Colvard MD, Bishop J, Weissman D, Gargiulo A (1986) Cardizem induced gingival hyperplasia: a report of two cases. Periodontal Case Reports 8: 67–68PubMedGoogle Scholar
  28. Corsing C, Varchmin G, Stoepel K (1987) Once-daily nitrendipine: Therapy in long-term patients with essential hypertension (mild to moderate), Efficacy, and tolerance. J Cardiovasc Pharmacol 99 (Suppl. 4): S136–S139CrossRefGoogle Scholar
  29. Cucchi G, Giugni R (1988) Gengivite ipertrofica da diltiazem. Minerva Cardioangiol 36: 509–510PubMedGoogle Scholar
  30. Dagher E, Dumont L, Chartrand C (1989) Positive hemodynamic interaction between amrinone and diltiazem in anesthetized dogs. Can J Physiol Pharmacol 67: 1092–1097PubMedCrossRefGoogle Scholar
  31. Deck K, Stoepel K, Leibowitz D, Taylor R, Vanow S (1984) Some aspects of the clinical pharmacology of nitrendipine. In: Scriabine A, Vanov S, Deck K (eds) Nitrendipine. Urban & Schwarzenberg, Baltimore, pp 397–407Google Scholar
  32. De Medina A, Biasinin O, Rivera A, Sampera A (1986) Nifedipine and myoclonic dystonia. Ann Intern Med 104: 125PubMedGoogle Scholar
  33. Dubois C, Blanchard D, Loria Y, Moreau M (1987) Clinical trial of a new antihypertensive drug, nicardipine: Efficacy and tolerance in 29,104 patients. Curr Ther Res 42: 727–736Google Scholar
  34. Duffy J, Macdonald G (1987) The antihypertensive efficacy of nifedipine alone and in combination in general practice. Curr Med Res Opin 10: 566–572PubMedCrossRefGoogle Scholar
  35. Dünschede HB, Corsing C, Schmitz H (1986) Langzeitbehandlung der Hypertonie mit Nitrendipin. In: Distler A (ed) Calcium-Antagonisten in der Hochdrucktherapie, Schattauer, Stuttgart, S183–S190Google Scholar
  36. Ebner F, Donath M (1980) Mode d’action et efficacit de làdalate. Cone Med 102 [Suppl 21]: 22–28Google Scholar
  37. Esper RJ, Maehado RA, Esper RC, Baglivo HP, Menna J (1987) Dose Assessment and long-term effectiveness of nitrendipine in the treatment of mild to moderate hypertensive patients. J Cardiovasc Pharmacol 9 [Suppl 4]: S164–S168CrossRefGoogle Scholar
  38. Fisher JR, Padnick MB, Olstem S (1983) Nifedipine and erythromelalgia. Ann Intern Med 98: 671–672PubMedGoogle Scholar
  39. Forette F, McClaran J, Hervy MP, Bouchacourt P, Henry JF (1989) Nicardipine in elderly patients with hypertension: A review of experience in France. Am Heart J 117: 256–261PubMedCrossRefGoogle Scholar
  40. Freedman SB, Richmond DR, Kelly DT (1982) Long-term follow-up of verapamil and nitrate treatment for coronary artery spasm. Am J Cardiol 50: 711–715PubMedCrossRefGoogle Scholar
  41. Frishman WH, Charlap S, Goldberger J, Kimmel B, Stroh J, Dorsa F, Allen L, Strom J (1985) Comparison of diltiazem and nifedipine for both angina pectoris and systemic hypertension. Am J Cardiol 56: 41H–46HPubMedCrossRefGoogle Scholar
  42. Furlanello F, Disertori M, Vergara G, Del Favero A (1980) Study on the electrophysiological effects of nifedipine in man. In: Puech P, Krebs R (eds) 4th International Adalat Symposium. Excerpta Medica, Amsterdam, pp 227–235Google Scholar
  43. Gill JS, Zezulka AV, Beevers M, Beevers DG (1986) An audit of nifedipine in a hypertension clinic. J Clin Hosp Pharmacy 11: 107–116Google Scholar
  44. Giustiniani S, Robustelli F (1987) Hyperplastic gingivitis during diltiazem therapy. Int J Cardiol 15: 247–249PubMedCrossRefGoogle Scholar
  45. Gless KH (1986) Antihypertensive Kombinationstherapie mit Reserpin. Therapiewoche 36: 3253–3259Google Scholar
  46. Goto Y (1986) Clinical investigation of a long-acting formulation of nifedipine in essential hypertension. In: Kelly DT (1986) II. Asian Pacific Adalat Symposium, ADIS press Auckland, pp 174–181Google Scholar
  47. Gottlieb SO, Ouyang P, Achuff SC, Baughman KL, Traill TA, Mellits ED, Weisfeldt ML, Gerstenblith G (1984) Acute nifedipine withdrawal: Consequences of preoperative and late cessation of therapy in patients with prior unstable angina. J Am Coll Cardiol 4: 382–388PubMedCrossRefGoogle Scholar
  48. Grayson HA, Kennedy JD (1982) Torsades de pointes and nifedipine. Ann Intern Med 97: 144PubMedGoogle Scholar
  49. Grino JM, Sabate I, Castelao AM, Alsina J (1986) Influence of diltiazem on cyclosporin clearance. Lancet 1: 1387PubMedCrossRefGoogle Scholar
  50. Guazzi M, Olivari MT, Polese A, Fiorentini C, Magrinin F, Moruzzi P (1977) Nifedipine - a new antihypertensive with rapid action. Clin Pharmacol Ther 22: 528–532PubMedGoogle Scholar
  51. Hamilton BP (1987) Treatment of essential hypertension with PN 200-110 (isradipine). Am J Cardiol 59: 141B–145BPubMedCrossRefGoogle Scholar
  52. Hare DL, Horowitz JD (1986) Verapamil herpatotoxicity: a hypersensitivity reaction. Am Heart J 111: 610–611PubMedCrossRefGoogle Scholar
  53. Heagerty Am, Swales J, Baksi A, Maclean D, Saltissi S, Curram JB, North PM (1988) Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Brit Med J 296: 468–472CrossRefGoogle Scholar
  54. Hedner T (1986) Calcium channel blockers: Spectrum of side effects and drug interactions. Acta Pharm Toxicol 58 [Suppl 2]: 119–130CrossRefGoogle Scholar
  55. Heinzl S (1989) Nisoldipin - Ein koronarselektiver Calciumantagonist. Arzneimitteltherapie 7 [Suppl 5]: 1–16Google Scholar
  56. Herrington DM, Insley BM, Weinmann GG (1986) Nifedipine overdose. Am J Med 81: 344–346PubMedCrossRefGoogle Scholar
  57. Hicks CB, Abraham K (1985) Verapamil and myoclonic dystonia. Ann Intern Med 103: 154PubMedGoogle Scholar
  58. Hossack KF (1982) Conduction abnormalities due to diltiazem. New Engl J Med 307: 953–954PubMedGoogle Scholar
  59. Italian-Belgian Isradipine Study Group (1989) Multicenter evaluation of the safety and efficacy of isradipine in hypertension. Am J Med 86 [Suppl 4A]: 94–97CrossRefGoogle Scholar
  60. Jain AK, McMahon FG, Ryan JR, Maronde R, Vlachakis N, Mroczek W (1984) Efficacy and safety of nitrendipine in patients with severe hypertension: a multiclinic study. J Cardiovasc Pharmacol 6 [Suppl 7]: S1053–S1059PubMedCrossRefGoogle Scholar
  61. Jee LD, Opie LH (1984) Nifedipine for hypertension and angina pectoris: interactions during combination therapy. In: Opie LH (ed) Calcium antagonists and cardiovascular disease. Raven, New York, pp 339–346Google Scholar
  62. Jones CR, Rae AP, Been M, deVane PJ, Jamieson RR, Hornung RS, Hillis WS (1985) Electrophysiological effects of felodipine in combination with metoprolol. Drugs 29 [Suppl 2]: 81–86PubMedCrossRefGoogle Scholar
  63. Kahn JK (1986) Nifedipine-associated acute psychosis. Am J Med 81: 705–706PubMedCrossRefGoogle Scholar
  64. Keyser P de, Bouv J, Clement D, Degraef R, Meurant JP, Rorive G, van Thillo J (1989) Isradipine in essential hypertension: the Belgian General Practitioners’ Study. Am J Med 86 [Suppl 4A]: 103–109PubMedCrossRefGoogle Scholar
  65. Kilborn JR, Battellochi S, Larribaud J, Morselli PL (1979) Preliminary clinical report on diltiazem in French patients suffering from angina. In: New drug therapy with a calcium antagonist. Excerpta Medica, Amsterdam, pp 129–140Google Scholar
  66. Kimbel KH (1983) Unerwünschte Wirkungen von Kalziumantagonisten. In: Magometschnigg D (ed) Kalziumantagonisten in der Therapie der arteriellen und pulmonalen Hypertonie. Uhlen, Wien, pp 135–140Google Scholar
  67. Kiowski W, Bertel O, Braun H (1990) Antihypertensive Monotherapie mit Nitrendipin in der Praxis. Therapiewoche 40: 61–65Google Scholar
  68. Kiowski W, Bertel O, Braun H (1988) Antihypertensive monotherapy with nitrendipine in general practice. J Cardiovasc Pharmacol 12 (Suppl. 4): S149–S153PubMedCrossRefGoogle Scholar
  69. Kirch W, Santos SR, Geller M, Mönig H, Stenzel J, Ohnhaus EE (1988) Influence of nitrendipine and verapamil on plasma levels, urinary excretion, and beta-blocking effect of metoprolol. Cardiovasc Drugs Ther 2: 205–209PubMedCrossRefGoogle Scholar
  70. Kirch W, Kleinbloesem CH, Beiz GG (1990) Drug interactions with calcium antagonists. Pharmacol Ther 45: 109–136PubMedCrossRefGoogle Scholar
  71. Kirkendall WM (1988) Comparative Assessment of first-line agents for treatment of hypertension. Am J Med 84 [Suppl 3B]: 32–41CrossRefGoogle Scholar
  72. Koch G (1980) Beta-receptor and calcium blockade in ischemic heart disease: effects on systemic and pulmonary hemodynamics and on plasma catecholamines at rest and during exercise. In: Puech P, Krebs R (eds) 4th International Adalat Symposium. Excerpta Medica, Amsterdam, pp 131–142Google Scholar
  73. Koshy A, Hadengue A, Lee SS, Jiron MI, Lebrec D (1987) Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis. Clin Pharmacol Ther 42: 295–298PubMedCrossRefGoogle Scholar
  74. Kozeny GA, Ragona BP, Bansal VK, Hurleg RM, Dixon DW, Vertuno LL, Hano JE (1986) Myocardial infarction with normal results of coronary angiography following diltiazem withdrawal. Am J Med 80: 1184–1186PubMedCrossRefGoogle Scholar
  75. Kuhlmann J (1985) Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin. Clin Pharmacol Ther 38: 667–673PubMedCrossRefGoogle Scholar
  76. Kuramoto K (1989) Double-blind studies of calcium antagonists in the treatment of hypertension in Japan. J Cardiovasc Pharmacol 13 (Suppl. l): 29–35CrossRefGoogle Scholar
  77. Lederman D, Lumerman H, Reuben S, Freedman P (1984) Gingival hyperplasia associated with nifedipine therapy. Oral Surg 57: 620–622PubMedCrossRefGoogle Scholar
  78. Levenson JL, Kennedy K (1985) Dysomia, dysgeusia and nifedipine. Ann Intern Med 102: 135–36PubMedGoogle Scholar
  79. Lewis GRJ (1986) Long-term results with verapamil in essential hypertension and its influence on serum lipids. Am J Cardiol 57: 35D–38DPubMedCrossRefGoogle Scholar
  80. Lewis JG (1983) Adverse reactions to calcium antagonists. Drugs 25: 196–222PubMedCrossRefGoogle Scholar
  81. Lipman J, Jardine I, Roos C, Dreosti L (1982) Intravenous calcium chloride as an antidote to verapamil-induced hypotension. Intensive Care Med 8: 55–57PubMedCrossRefGoogle Scholar
  82. Luderschmidt C (1987) Nebenwirkungen von Calciumantagonisten. Dtsch Med Wochenschr 112: 279PubMedGoogle Scholar
  83. Lydtin H, Trenkwalder P (1988) Calciumantagonisten. Arzneimittelinteraktionen bei der Therapie mit Calcium-Antagonisten. Springer, Berlin Heidelberg New York Tokyo, pp 242–248Google Scholar
  84. Macdonald G, Leger PBST (1987) Lack of a relationship between age and the antihypertensive effects of nifedipine tablets in patients up to 70 years of age. Brit J Clin Practice 41: 659–662Google Scholar
  85. Maisel AS, Motulsky HJ, Insel PA (1985) Possible additive competition of alpha-adrenergic receptors. New Engl J Med 312: 167–170PubMedCrossRefGoogle Scholar
  86. Marley JE (1989) Safety and efficacy of nifedipine 20 mg tablets in hypertension using electronic data collection in general practice. J Royal Soc Med 82: 272–275Google Scholar
  87. Mayer U, Buhl N, Sachs H, Sigl H (1985) Tödliche Vergiftung mit Verapamil in Retard-Form. Dtsch Med Wochenschr 110: 1293–1296PubMedCrossRefGoogle Scholar
  88. McGovern B, Garan H, Ruskin JN (1986) Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann Intern Med 104: 791–794PubMedGoogle Scholar
  89. Mehta J, Lopez LM (1986) Calcium-blocker withdrawal phenomenon: Increase in affinity of alpha2-adrenoceptors for agonist as a potential mechanism. Am J Cardiol 58: 242–246PubMedCrossRefGoogle Scholar
  90. Midtbø K, Hals O, Lauve O, Van der Meer J, Storstein L (1986) Studies on verapamil in the treatment of essential hypertension: a review. Br J Clin Pharmacol 21: 165S–171SPubMedGoogle Scholar
  91. Midtbø K, Lauve O, Hals O (1988) No metabolic side effects of long-term treatment with verapamil in hypertension. Angiology 12: 1025–1029CrossRefGoogle Scholar
  92. Millard RW, Lathrop DA, Grupp G, Ashraf M, Grupp I, Schwartz A (1982) Differential cardiovascular effects of calcium channel blocking agents: Potential mechanisms. Am J Cardiol 49: 499–505PubMedCrossRefGoogle Scholar
  93. Morris DL, Goldschlager N (1983) Calcium infusion for reversal of adverse effects of intravenous verapamil. J Amer Med Ass 249: 3212–3213CrossRefGoogle Scholar
  94. Mroczek WJ, Burris JF, Allenby KS (1988) Nitrendipine in severe hypertension. Hypertension 11 [Suppl 1]: 1225–1228Google Scholar
  95. Murray TS, Langan J, Coxhead PF, Levinson N (1986) Long-term effects of nicardipine in the treatment of essential hypertension. Br J Clin Pharmacol 22: 249S–257SGoogle Scholar
  96. Nelson GIC, Silke B, Ahuja RC, Hussain M, Forsyth D, Taylor SH (1984) The effect on left ventricular performance of nifedipine and metoprolol singly and together in exercise-induced angina pectoris. Eur Heart J 5: 67–79PubMedGoogle Scholar
  97. Ohnmeiss H, Nazzari M (1986) Side effects of calcium antagonists. Am J Nephrol 6 [Suppl 1]: 81–86PubMedCrossRefGoogle Scholar
  98. Olivari MT, Barturelli C, Polese A, Fiorentini C, Moruzzi P, Guazzi MD (1979) Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation 59: 1056–1062PubMedGoogle Scholar
  99. Opie LH (1986) Fluid retention with nifedipine in antihypertensive therapy. Lancet 11: 1456CrossRefGoogle Scholar
  100. Parent R, Chiasson JL, Larochelle P (1989) Hemodynamic and endocrine effects of acute and chronic administration of nifedipine. J Clin Pharmacol 29: 107–111PubMedGoogle Scholar
  101. Parker JO, Enjalbert M, Bernstein V (1988) Efficacy of the calcium antagonist isradipine in angina pectoris. Cardio vase Drugs Ther 1: 661–664CrossRefGoogle Scholar
  102. Pieper JA, Miller JH (1984) Serum protein binding interactions between propranolol and calcium channel blockers. Drug Intell Clin Pharm 18: 492 No. 8Google Scholar
  103. Piepho RW, Culbertson VL, Rhodes RS (1987) Drug interactions with the calcium-entry blokkers. Circulation 75 [Suppl V]: V181–V194PubMedGoogle Scholar
  104. Pool PE, Seagren SC, Salel AF (1985) Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 56: 86H–91HPubMedCrossRefGoogle Scholar
  105. Raftos J (1980) Verapamil in the long-term treatment of angina pectoris. Med J Aust 2: 78–80PubMedGoogle Scholar
  106. Ramon Y, Behar S, Kishon Y, Engelberg IS (1984) Gingival hyperplasia caused by nifedipine - a preliminary report. Int J Cardiol 5: 195–204PubMedCrossRefGoogle Scholar
  107. Rauramaa R, Taskinen E, Seppänen K, Rissanen V, Salonen R, Venäläinen JM, Salonen JT (1988) Effects of calcium antagonist treatment on blood pressure, lipoproteins, and prostaglandins. Am J Med 84 [Suppl 3B]: 93–96CrossRefGoogle Scholar
  108. Riegel W, Hörl WH, Heidland A (1986) Long-term effects of nifedipine on carbohydrate and lipid metabolism in hypertensive hemodialyzed patients. Klin Wochenschr 64: 1124–1130PubMedCrossRefGoogle Scholar
  109. Ritchie LD, Vandenburg MJ, Harrington L, MacGregor A (1988) Lowdose, slow-release nifedipine in hypertension: a multicenter primary care study. J Cardio vase Pharmacol 12 (Suppl. 6): S193–S194Google Scholar
  110. Roy LF, East DS, Browning FM, Shaw D, Ogilvie RI, Cardella C, Leenen FH (1989) Short-term effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart- transplant and kidney-transplant patients. Clin Pharmacol Ther 46: 657–667PubMedCrossRefGoogle Scholar
  111. Rüegg PC, Nelson DJ (1989) Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris. Am J Med 86 [Suppl 4A]: 70–74PubMedCrossRefGoogle Scholar
  112. Russell RP (1988) Side effects of calcium channel blockers. Hypertension 11 [Suppl 2]:II42–II44PubMedGoogle Scholar
  113. Samuel P, Kirkendall W, Schaefer EJ, Chin B, Schoenfeld BH, Gonasun LM, Lieberman S (1988) Effects of isradipine, a new calcium antagonist, versus hydrochlorothiazide on serum lipids and apolipoproteins in patients with systemic hypertension. Am J Cardiol 62: 1068–1071PubMedCrossRefGoogle Scholar
  114. Schäfer SG, Schuhmann G, Doering W, Fichtl B (1985) Influence of quinidine on the intestinal secretion of digoxin and digitoxin in guinea pigs. Chem Biol Interact 55: 203–213PubMedCrossRefGoogle Scholar
  115. Schick EC, Liang C, Heupler FA, Kahl FR, Kent KM, Kerin NZ, Noble RJ, Rubenfire M, Tabatznik B, Terry RW (1982) Randomized withdrawal from nifedipine: Placebo-controlled study in patients with coronary artery spasm. Am Heart J 104: 690–697PubMedCrossRefGoogle Scholar
  116. Sagues Gabarro F et grupo de Trabajo (1988) Estudio abierto para volorar la eficacia y tolerancia de la nifedipina de acción prolongada en el tratamiento de la hipertensión arterial esencial levemoderada. Med Clin (Bare) 91: 493–495Google Scholar
  117. Scolnick B, Brinberg D (1985) Diltiazem and generalized lymphadenopathy. Ann Intern Med 102: 558PubMedGoogle Scholar
  118. Silvestri E, Veraldi S, Piferi M, Sala F, Bencini L, Marini D (1988) Iperplasia gengivale da difenilidantoina, ciclosporina a e nifedipina. Minerva Stomatol 37: 189–192PubMedGoogle Scholar
  119. Strubelt O (1984) Antidotal treatment of the acute cardiovascular toxicity of verapamil. Acta Pharmacol 55: 231–237CrossRefGoogle Scholar
  120. Strubelt O (1989) Vergiftungen durch Verapamil und andere Calciumantagonisten. Dtsch Med Wochenschr 114: 1623–1627PubMedCrossRefGoogle Scholar
  121. Subramanian VB, Raftery EB (1981) The role of verapamil in chronic stable angina and hypertension. 30th Annual Scientific Session, American College of Cardiology, March 15–19, San FranciscoGoogle Scholar
  122. Subramanian VB, Bowles MJ, Davies AB, Khurmi NS, Raftery EB (1981) Double blind comparison of verapamil and nifedipine in chronic stable angina. Circulation 64 [Suppl IV]: 150Google Scholar
  123. Subramanian VB, Bowles MJ, Khurmi NS, Davies AB, O’Hara MJ, Raftery EB (1983) Calcium antagonist withdrawal syndroms: objective demonstration with frequency-modulated ambulatory ST-segment monitoring. Br Med J 286: 520–521CrossRefGoogle Scholar
  124. Sundstedt CD, Rüegg PC, Keller A, Waite R (1989) A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension. Am J Med 86 [Suppl 4A]: 98–102PubMedCrossRefGoogle Scholar
  125. Taylor SH, Jackson NC, Allen J, Pool PE (1987) Efficacy of a new calcium antagonist PN 200–110 (isradipine) in angina pectoris. Am J Cardiol 59: 123B–129BPubMedCrossRefGoogle Scholar
  126. Thomson BM, Pannell LK (1981) The analysis of verapamil in postmortem specimens by HPLC and GC. J Analyt Toxicol 5: 105–109Google Scholar
  127. Tourkantonis A, Lasaridis A (1986) Der antihypertensive Effekt von Nitrendipin in verschiedenen Altersgruppen. In: Distler A (ed) Calcium-Antagonisten in der Hochdrucktherapie, Schattauer, Stuttgart, S205–S219Google Scholar
  128. Trohmann RG, Estes DM, Castellanos A, Palomom AR, Myerburg RJ, Kessler KM (1986) Increased quinidine plasma concentrations during administration of verapamil: a new quinidine verapamil interaction. Am J Cardiol 57: 706–707CrossRefGoogle Scholar
  129. Trost BN, Weidmann P (1987) Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens 5 [Suppl 4]: S81–S104CrossRefGoogle Scholar
  130. Trost BN, Weidmann P (1988) Metabolic effects of calcium antagonists in humans, with emphasis on carbohydrate, lipid, potassium, and uric acid homeostases. J Cardiovasc Pharmacol 12 [Suppl 6]: S86–S92PubMedCrossRefGoogle Scholar
  131. Weber MA (1987) A one-year experience with the calcium channel blocking agent, nitrendipine, in patients with essential hypertension: Report of a multicenter study. J Cardiovasc Pharmacol 9 [Suppl 4]: S182–S189Google Scholar
  132. Weller JP, Wolf M (1986) Eine tödliche Verapamil-Vergiftung. Beitr Gerichtl Med 44: 271–275PubMedGoogle Scholar
  133. Wiese J, Klug E, Schneider V, Tenczer J, Beyer KH (1988) Tödliche Diltiazemvergiftung. Z Rechtsmed 100: 271–276PubMedCrossRefGoogle Scholar
  134. Winer N, Thys-Jacobs S, Kumar R, Davidson WD, Grayson M, Harris C, Walker D, Itskovitz H, Gonasun L (1987) Evaluation of isradipine (PN 200-110) in mild to moderate hypertension. Clin Pharmacol Ther 42: 442–448PubMedCrossRefGoogle Scholar
  135. Witchitz S, Serradimigni (1989) Lisinpril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. J Hum Hypertension 3: 29–33Google Scholar
  136. Wolf A, Corsing C (1991) Zur antihypertensiven Wirksamkeit und Verträglichkeit von Nitrenipin. Therapiewoche, im DruckGoogle Scholar
  137. Wolf A, Corsing C ( 1991 a) Zur antihypertensiven Wirksamkeit und Verträglichkeit von Nitrendipin, 2. Mitteilung. Zeitschr Allgemeinmedizin, im DruckGoogle Scholar
  138. Wolf E (1987) Nutzen und Risiko einer antianginösen Therapie mit Gallopamil in der täglichen Praxis. Therapiewoche 37: 2372–2380Google Scholar
  139. Zachariah PK, Brobyn R, Kann J, Levy B, Margolis R, McMahon FG, Reeves R, Sperling DC, Sweet D, Zager P, Zellner SR (1988) Comparison of quality of life on nitrendipine and propranolol. J Cardiovasc Pharmacol 12 (Suppl. 4): S29–S35PubMedCrossRefGoogle Scholar
  140. Zawada ET, Williams L, McClung DE, TerWee JA, Horning J, McNultry R, Thomas M, Simmons J (1987) Renal-metabolic consequences of antihypertensive therapy with diltiazem versus hydrochlorothiazide. Miner Electrolyte Metab 13: 72–77PubMedGoogle Scholar
  141. Zezulka AV, Gill JS, Beevers DG (1984) Diabetogenic effects of nifedipine. Br Med J 289: 437–438CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • G. Bönner

There are no affiliations available

Personalised recommendations